Connect your AI

Pacira BioSciences, Inc. PCRX Acquisitions

Acquisitions at other companies

Avanos MedicalAVNS

$3.4M+41.7%

Other financials

Income statement

Revenue$177.4M+5.0%

Gross profit$141.0M+4.7%

Operating income$6.9M+247%

Net income$2.9M-39.4%

EPS (diluted)$0.07-30.0%

Balance sheet

Cash & equivalents$144.3M-49.1%

Total debt$411.2M+15.3%

Total equity$653.9M-18.1%

Total assets$1.2B-23.8%

Cash flow

Operating cash flow$25.7M-27.6%

CapEx$2.7M-68.1%

Free cash flow$23.0M-14.7%

Valuation

Market cap$942.78M-14.5%

Enterprise value$1.21B+2.6%

P/E183.5×—

P/S1.3×-0.3×

Profitability

Gross margin79.3%+1.7pp

Operating margin3.3%—

Net margin0.7%—

FCF margin18.1%-4.6pp

Returns & leverage

Return on equity0.7%—

Debt / equity0.6×+0.2×

Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s acquisitions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Pacira BioSciences, Inc.'s acquisitions?: Pacira BioSciences, Inc. (PCRX) reported acquisitions of $335K in Q1 2026.
How has Pacira BioSciences, Inc.'s acquisitions changed year-over-year?: Pacira BioSciences, Inc.'s acquisitions decreased by 98.0% year-over-year, from $16.7M to $335K.
What is the long-term trend for Pacira BioSciences, Inc.'s acquisitions?: Over 3 years (2021 to 2024), Pacira BioSciences, Inc.'s acquisitions has grown at a -100.0% compound annual growth rate (CAGR), from $420.04M to $0.
What does acquisitions mean?: Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.